Tolerability of perampanel: A retrospective study at the department of psychiatry
Epilepsy & Behavior · 2024
DOI: 10.1016/j.yebeh.2024.109797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Taiki Matsuyama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Wakkanai City Hospital, Wakkanai, Japan. Hauptthemen laut MEDLINE: Pyridones, Nitriles, Anticonvulsants, Mental Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: We aimed to identify factors that contribute to the discontinuation of perampanel. METHODS: We retrospectively analyzed patients with epilepsy at the Department of Psychiatry, Hokkaido University Hospital. We evaluated the factors contributing to perampanel discontinuation as primary outcomes using Cox proportional hazards regression. Then, we explored the components contributing to the primary outcomes using logistic regression analysis. RESULTS: A total of 118 patients were included, 44.9% of whom discontinued participation, 22.0% had intellectual disability, and 23.7% had a psychiatric disorder other than intellectual disability. Adverse effects occurred in 65% of the patients, 23.7% had psychiatric adverse effects (PAE), and 49.2% had common adverse effects (CAE). The effect of PER to suppress seizures was confirmed in 65.3% of them. Discontinuation was influenced by non-response (Hazard Ratio (HR) 6.70, 95% Confidence Interval (CI) 3.42-13.1), the occurrence of PAE (HR 3.68, 95% CI 1.89-7.16), CAE (HR 1.90, 95% CI 1.06-3.41), and comorbid psychiatric disorders (HR 2.35, 95% CI 1.21-4.59). Moreover, comorbid intellectual disability correlated with a low risk of PAE (OR 0.19, 95% CI 0.04-0.89). CONCLUSION: The discontinuation of perampanel is influenced by poor efficacy and the occurrence of common/psychiatric adverse effects. The discontinuation of perampanel is influenced by poor efficacy and the occurrence of common/psychiatric adverse effects. Consideration of factors contributing to perampanel discontinuation may assist in determining the indication for perampanel treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Wakkanai City Hospital, Wakkanai, Japan.
- Department of Psychiatry, Hokkaido University Hospital, Sapporo, Japan. Electronic address: toruhorinouchi1234@gmail.com.
- Department of Psychiatry, Hokkaido University Hospital, Sapporo, Japan.
Zitieren
APA
Matsuyama, T., Horinouchi, T., Nakamura, Y., Ishikawa, S., Hashimoto, N., & Kusumi, I. (2024). Tolerability of perampanel: A retrospective study at the department of psychiatry. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.109797
Vancouver
Matsuyama T, Horinouchi T, Nakamura Y, Ishikawa S, Hashimoto N, Kusumi I. Tolerability of perampanel: A retrospective study at the department of psychiatry. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.109797
BibTeX
@article{Matsuyama2024,
author = {Matsuyama, Taiki and Horinouchi, Toru and Nakamura, Yuichi and Ishikawa, Shuhei and Hashimoto, Naoki and Kusumi, Ichiro},
title = {Tolerability of perampanel: A retrospective study at the department of psychiatry},
journal = {Epilepsy & Behavior},
year = {2024},
doi = {10.1016/j.yebeh.2024.109797}
}
EUVIMED